Zoetis Inc. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Zoetis Inc. treasury stock, value, acquired, cost method for the quarter ending 2026-06-30 was $558.00M, a 63.64% increase year-over-year.
- Zoetis Inc. treasury stock, value, acquired, cost method for the quarter ending 2026-03-31 was $612.00M, a 36.91% increase year-over-year.
- Zoetis Inc. treasury stock, value, acquired, cost method for the quarter ending 2025-12-31 was $2.08B, a 272.76% increase year-over-year.
- Zoetis Inc. treasury stock, value, acquired, cost method for the quarter ending 2025-09-30 was $381.00M, a 10.77% decline year-over-year.
- Zoetis Inc. treasury stock, value, acquired, cost method for fiscal 2025 was $3.25B, a 74.21% increase from fiscal 2024.
- Zoetis Inc. treasury stock, value, acquired, cost method for fiscal 2024 was $1.86B, a 69.24% increase from fiscal 2023.
- Zoetis Inc. treasury stock, value, acquired, cost method for fiscal 2023 was $1.10B, a 30.87% decline from fiscal 2022.
- Zoetis Inc. treasury stock, value, acquired, cost method for fiscal 2022 was $1.59B, a 114.54% increase from fiscal 2021.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2026-06-30 | $558.00M 10-Q · filed 2026-08-06 | $3.63B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $612.00M 10-Q · filed 2026-05-07 | $3.41B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.08B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $3.25B 10-K · filed 2026-02-12 |
| 2025-09-30 | $381.00M 10-Q · filed 2025-11-04 | $1.73B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $341.00M 10-Q · filed 2026-08-06 | $1.77B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $447.00M 10-Q · filed 2026-05-07 | $1.97B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $558.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.86B 10-K · filed 2026-02-12 |
| 2024-09-30 | $427.00M 10-Q · filed 2025-11-04 | $1.54B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $538.00M 10-Q · filed 2025-08-05 | $1.37B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $342.00M 10-Q · filed 2025-05-06 | $1.16B derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $238.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.10B 10-K · filed 2026-02-12 |
| 2023-09-30 | $252.00M 10-Q · filed 2024-11-04 | $1.27B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $327.00M 10-Q · filed 2024-08-06 | $1.39B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $285.00M 10-Q · filed 2024-05-02 | $1.52B derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $405.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $1.59B 10-K · filed 2025-02-13 |
| 2022-09-30 | $377.00M 10-Q · filed 2023-11-02 | $1.39B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $451.00M 10-Q · filed 2023-08-08 | $1.21B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $361.00M 10-Q · filed 2023-05-04 | $923.00M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $198.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $743.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $198.00M 10-Q · filed 2022-11-03 | $545.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $166.00M 10-Q · filed 2022-08-04 | $347.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $181.00M 10-Q · filed 2022-05-05 | $181.00M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $250.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $426.00M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $576.00M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $250.00M 10-Q · filed 2021-05-06 | $726.00M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $176.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $626.00M 10-K · filed 2022-02-15 |
| 2019-09-30 | $150.00M 10-Q · filed 2020-11-05 | $600.00M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $150.00M 10-Q · filed 2020-08-06 | $593.00M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $150.00M 10-Q · filed 2020-05-06 | $658.00M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $150.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $698.00M 10-K · filed 2021-02-16 |
| 2018-09-30 | $143.00M 10-Q · filed 2019-11-07 | $673.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $215.00M 10-Q · filed 2019-08-06 | $655.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $190.00M 10-Q · filed 2019-05-02 | $565.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $125.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $500.00M 10-K · filed 2020-02-13 |
| 2017-10-01 | $125.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $450.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-07-02 | $125.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $399.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-04-02 | $125.00M 10-Q · filed 2018-05-02 | $349.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $75.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $300.00M 10-K · filed 2019-02-14 |
| 2016-10-02 | $74.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $276.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-07-03 | $75.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $252.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-04-03 | $76.00M 10-Q · filed 2017-05-04 | $228.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $51.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $199.00M 10-K · filed 2018-02-15 |
| 2015-09-27 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $148.10M derived: sum of 4 quarters · filed 2016-11-03 |
| 2015-06-28 | $51.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $98.10M derived: sum of 4 quarters · filed 2016-08-05 |
| 2015-03-29 | $47.00M 10-Q · filed 2016-05-06 | $47.30M derived: sum of 4 quarters · filed 2016-05-06 |
| 2014-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $500.00K 10-K · filed 2016-02-24 |
| 2014-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | |
| 2014-06-29 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | |
| 2014-03-30 | $200.00K 10-Q · filed 2015-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |